11 June 2026
11 June 2026
Dr Arun Swaminathan tells Salong Debbarma how COYA 302’s FDA fast track status is shaping Coya’s next steps, from accelerating ALSTARS enrolment to aligning earlier with regulators on a path to clinically meaningful benefit.
Parabilis’ US listing means the biotech IPO record has been broken twice in as many months as public listings continue hot streak.
If approved, adrabetadex would be the third addition to the I-NPC treatment paradigm.
XtalPi stands to receive further payments based on clinical and commercial milestones, as well as future royalties.
The application is supported by data from the Phase III OCEANIC-STROKE study.
Phase III data suggest oral PCSK9 inhibitor enlicitide delivers substantial LDL-C lowering without compromising glycemic control.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
